Invest in QUANTGENE

Engage!

Join our live town halls on X (Twitter) every week: CLICK HERE

Book a 1:1 meeting with our Founder & CEO if you are considering an investment of $10k or more: https://calendly.com/johannesbhakdi/1-1-with-jo-bhakdi

Invest $1,000 and get $500 off QX cancer screening. It can save your life:

$1,495 instead of $1,995. How it works: 1) invest $1,000 or more. 2) Write us an email to [email protected] 3) We will send you your investor discount code and link to QX checkout.

Qx is available in the United States across all states except New York.

Our products save lives.

Quantgene Qx is the world’s first medical solution that intelligently detects cancer signals across a wide range of diagnostic signals. It combines Quantgene’s genomics platforms with a new medical intelligence engine that uses the patient’s medical history, family history, preventive screening status as well as advanced imaging data (if available) to triangulate signals of over 50 cancer types at an unprecedented level of precision. Based on our early pilot programs, we are confident that with the first 1,000 Qx customers we will be able to show the highest cancer detection rate ever achieved. Many of the nation’s leading cancer screening experts are watching us. We have good reason to believe Qx won’t disappoint. 

Get Qx HERE

Quantgene’s Intelligent Genomics has already started saving lives. Ask Ashley, whose breast cancer was detected by Quantgene’s Qx system in an early commercial pilot. Ashley is 39, too young for standard of care preventive cancer screenings. We know that there are thousands of patients like Ashley out there. These patients need Qx.

Get Qx HERE

Once we hit our 1,000 patient milestone in 2024, Qx is on its way to END CANCER.

Our solutions transform hospitals.

Quantgene Qi is the world’s first turnkey solution to bring precision genomics inside hospital systems. Qi turns isolated genetic test ordering into a seamless hospital solution: it combines laboratory infrastructure, cloud & bioinformatics as well as revenue cycle management and clinical implementation. Qi is a holistic system that unlocks new revenue streams for hospitals while expanding clinical staffing and improving patient care. Through an intelligent commercial management system, Qi is fully paid for and adds to the bottom line of hospitals instead of draining already tight budgets.

If you are part of the medical or administrative leadership of a hospital, learn more about Qi here.

Qi isn't a theory. It's a system whose components have already been vetted by clinical decision makers in some of the world's best hospital and cancer systems. Pre-launch, we already have 6 deals on the table, each of which would set a new standard for genomic medicine in America. The reason is simple: Patients need Qi and Hospitals WANT Qi.

Once we close the first deals in 2024, Qi creates a new genomics infrastructure designed to REACH 1 BILLION PATIENTS within a decade.

We are ready for prime time.

After 8 years of R&D, we have prepared two platforms that have the potential to end cancer as we know it: Qi for hospitals and Qx for patients. For Qi, our hospital deal pipeline already exceeds $200mm in deal value. For Qx, we reached distribution partnerships in 2023 that allow us to reach over 70,000 qualified patients in 2024. 

Our Intelligent Genomics platform is now ready for patients. That's a very big deal. It took us 8 years and $36mm in R&D investments to get to this point, and we are very proud of it. In our commercial pilots, we already saved the first life (read Ashley's story below).

Our technology is tested and mission-focused.

Quantgene's Intelligent Genomics platforms have come a long way since 2015. $36mm and a focused effort went into the construction of the Alpha Lab with the first unified intelligent genomics sample workflow, Quantgene’s DeepGen genomic cancer detection system covered in many peer-reviewed publications, as well as 100s of proprietary technology components that bring everything together under one purpose: to end cancer for all.

The Quantgene Alpha Lab in Portland, OR is the world’s first genomics laboratory with a unified workflow across cfDNA multi-cancer signal detection, hereditary cancer genetics and pharmacogenomics. This allows us to achieve lower cost per sample at improved quality and patient convenience compared to conventional genomics workflows - a game-changer for delivering seamless and affordable Intelligent Genomics to all. 

Our R&D team of PHDs and engineers in Berlin, Germany leads the world in Intelligent Genomics system design. Their work allows us to transcend conventional genomics by combining multiple genomic cancer signals with other modalities, including far-reaching patient and family history, preventive screening status and advanced imaging results to detect cancer with a new level of precision. 

We work with the best.

Our cancer genomics research includes collaborators like Prof. Raz, Prof. Chambers and other clinicians who are working at some of the world’s leading cancer centers. Their passion and expertise have helped us to create one of the world's most advanced clinical genomics platforms.

Our expert advisors. investors and partners work at the nation’s premier clinical diagnostics and disruptive investment firms. Their advice and support remains crucial to our success.

Our team is committed to win - for You.

Our team is our greatest asset. With backgrounds from some of the world’s leading genomics companies and research institutions, we have proven that we are the only team in the industry that has the cohesion, expertise and determination to get the job done. For 8 years, Quantgene has pushed the frontier of Intelligent Genomics with only one goal in mind: to END CANCER.

Our market exceeds $1 Trillion.

Cancer is killing 1,600 Americans every single day. It destroys over $1T in economic value each year. Cancer diagnostics alone are a $132 billion market. Our Qx and Qi solutions can quickly reach the 30 million Americans most in need for genomic cancer protection, either through existing insurance coverage (Qi) or self-pay concierge care (Qx). With each of us currently having a 30% chance of dying of cancer, it’s an opportunity we have to seize.

Our competition got stuck with special interests.

In certain industries, you get paid to fail. Over the last 8 years, we have seen again and again how great technologies got sold, got stuck or got pivoted away from patients. Universal Cancer detection and intelligent genomics is not just a race for technology: it's also a fight for independence from special interests. Quantgene is the only leading genomics company that has remained in control of its own fate. Yes, we have an outstanding team and technology platform - but the real reason we are ready to launch is because special healthcare interests weren't able to stop us. Believe us, they have tried.

We project $1 billion in revenue by 2028.

We have tested and calibrated our solutions extensively over the last 2 years. In 2024, we want to bring personal cancer protection to the first 1,000 customers and implement the first 2 Qi solutions in hospitals. Both solutions are profitable from the outset, with 40%+ gross margins and enormous TAMs. A successful 2024 commercial launch can put Quantgene on track to become the fastest-growing, highest-grossing healthcare company in the world, with over $1 billion cumulative revenue within the next five years.

In order to become the fastest-growing healthcare company, we have to succeed in 2024. We need your support so we can acquire the first 1,000 Qx members who receive next-generation genomic cancer detection; and to close & implement the first 2 Qi hospital deals valued at ~$100mm combined revenue over the next five years. With these numbers, we also project to detect 10 early stage cancers and save our patient’s lives.

Praised by the press.

Don't let them stop us.

In our conversations with institutional healthcare and biotech investors, we have noticed a pattern: they love our technology, but hate the idea to commercialize them. Instead, they push us to change direction, add more data and prepare the company for sale to a large pharma or diagnostics conglomerate. They say that's the “proven path” for new genomics technologies. But we deeply disagree. Intelligent Genomics is now ready to save countless lives. We can't just sell out and see it being shelved in a corporate basement. If we want to stay true to our mission and KILL CANCER, we NEED to unlock an independent capital source. We need YOU to help us build the first healthcare company funded BY the people, so we can work FOR the people. 

Regardless if you want to become a Quantgene investor or not, please join us here to learn more about the problem of special interests in cancer innovation. It affects all of us.

Invest and make history.

Intelligent Genomics is opening a path into a future where cancer has ceased to be a major risk of death. There is not much doubt in the medical community that universal cancer detection would achieve this goal. Quantgene is the only company ready to open the path into this future. Please help us to get there.

We invite you to invest in Quantgene. By joining us, you are investing in one of the greatest opportunities and innovation leaps of our time: the End of Cancer.

Join our journey to create the first independent healthcare innovation company, push the frontiers of genomic intelligence and KILL CANCER.

Book a 1:1 meeting with the CEO

If you are considering an investment of $10k or more, you can book a 1:1 meeting with Quantgene's Founder & CEO Jo Bhakdi here:

https://calendly.com/johannesbhakdi/1-1-with-jo-bhakdi